JSPR Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc. (JSPR) is expected to report earnings on February 15, 2027, before the market open. The consensus earnings estimate is a loss of $7.01 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -36.4% since its last earnings release on November 16, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Jasper Therapeutics, Inc.
Jasper Therapeutics Inc., a biotechnology company focused on hematopoietic cell transplant therapies. Jasper Therapeutics Inc., formerly known as Amplitude Healthcare Acquisition Corporation, is based in REDWOOD CITY, Calif.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.